Effect of palonosetron (5HT-3 antagonist) and pantoprazole (proton pump inhibitor) against surgical esophagitis induced by forestomach and pylorus ligation in albino rats.
This study was embarked upon to evaluate the effects of pantoprazole and palonosetron on experimental esophagitis in albino wistar rats. Groups of rats, fasted for 36 h, were subjected to pylorus and forestomach ligation, supervened by treatment with normal saline (3 ml/kg, po, sham control), esophagitis control (3 ml/kg, po), pantoprazole (30 mg/kg, po), palonosetron (0.5 mg/kg, po), and their combination. Animals were sacrificed after 12 h and appraised for the volume of gastric juices, total acidity, free acidity, and esophagitis index. Esophageal tissues were further figured out biochemically for markers of oxidative stress and inflammatory mediators. The combination therapy comparably inhibited the esophagitis index (52.86%), gastric volume (66.04%), free acidity (43.76%), and total acidity (42.60%) in comparison with toxic control. The combination therapy also subsidized the biochemical and inflammatory markers to the purview less than toxic control. The morphological changes were scrutinized by scanning electron microscopy and were observed to demonstrate momentous protection by the amalgamation therapy. Combination therapy with pantoprazole and palonosetron flaunted sententious protection against experimental esophagitis.
Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, Lucknow, Uttar Pradesh, India.
A
A
Kumar
Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, Lucknow, Uttar Pradesh, India.
S
S
Gautam
Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, Lucknow, Uttar Pradesh, India.
J K
JK
Rawat
Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, Lucknow, Uttar Pradesh, India.
M
M
Singh
Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, Lucknow, Uttar Pradesh, India.
S A
SA
Saraf
Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, Lucknow, Uttar Pradesh, India gauravpharm@hotmail.com.
G
G
Kaithwas
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D001093:Arachidonate 15-Lipoxygenase / Q000097:blood / Q000378:metabolism; D015415:Biomarkers; D051545:Cyclooxygenase 1 / Q000097:blood / Q000378:metabolism; D051546:Cyclooxygenase 2 / Q000097:blood / Q000378:metabolism; D004359:Drug Therapy, Combination; D004941:Esophagitis / Q000188:drug therapy / Q000209:etiology*; D004947:Esophagus / Q000473:pathology / Q000648:ultrastructure; D007249:Inflammation / Q000188:drug therapy / Q000209:etiology; D007546:Isoquinolines / Q000008:administration & dosage / Q000627:therapeutic use*; D008026:Ligation; D000077924:Palonosetron; D000077402:Pantoprazole; D054328:Proton Pump Inhibitors / Q000627:therapeutic use; D011812:Quinuclidines / Q000008:administration & dosage / Q000627:therapeutic use*; D051381:Rats; D012702:Serotonin Antagonists / Q000627:therapeutic use; D013270:Stomach / Q000473:pathology* / Q000601:surgery
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D015415:Biomarkers; D007546:Isoquinolines; D054328:Proton Pump Inhibitors; D011812:Quinuclidines; D012702:Serotonin Antagonists; D000077924:Palonosetron; D000077402:Pantoprazole; D001093:Arachidonate 15-Lipoxygenase; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2
Esophagitis; interleukin; palonosetron; pantoprazole; serotonin